Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROpel: Olaparib plus Abiraterone in First-line mCRPC
jRCT2080224143Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Olaparib plus Abiraterone with Placebo plus Abiraterone (2 arms). Primary endpoint: Radiographic progression-free survival (rPFS). Started Nov 2018; status: completed.
02
Drugs
olaparibabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2080224143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224143.